NAD+ What the Research Actually Says: Evidence Review

Introduction

NAD+ research over the past decade has produced a lot of interesting biology, a moderate number of small human trials, and an enormous amount of marketing. This review walks through what’s actually been published in humans, what the trials measured, where the data is strongest, and where it’s far weaker than the marketing suggests.

The summary upfront: NAD+ precursor supplementation (mostly NR and NMN) reliably raises blood NAD+ levels in human trials. That’s the strongest, most reproducible finding. Clinical outcomes data is thinner and effect sizes have been modest. No trial has yet shown that NAD+ supplementation prevents disease, extends lifespan, or substitutes for established interventions like exercise, weight loss medications, or treatment of underlying conditions.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What’s the Size and Shape of the NAD+ Trial Literature?

As of 2025, PubMed shows roughly 30 to 40 completed human trials of NR or NMN, with several more in progress. Most trials enrolled 20 to 100 participants and ran for 8 to 24 weeks. The biggest published trials in humans are still under 200 patients.

Quick Answer: Over 30 published human trials of NR and NMN exist as of 2025, mostly with biomarker endpoints and sample sizes of 20 to 100 participants

Endpoints are mostly biomarkers: blood NAD+, sometimes muscle NAD+ via biopsy, sometimes mitochondrial function markers, sometimes insulin sensitivity, sometimes blood pressure. Patient-relevant outcomes like exercise capacity, cognitive function, and falls have been studied in smaller subsets with mixed results.

No NAD+ trial has used a hard endpoint like cardiovascular events, fractures, mortality, or progression to disease as a primary outcome. The trials have been hypothesis-generating rather than definitive.

This is normal for early-stage clinical research. The criticism isn’t that the trials are bad. It’s that the marketing built on these trials often overstates what they showed and ignores the fact that they’re hypothesis-generating rather than confirmatory.

What Did the Yoshino Et Al. NMN Trial Actually Show?

This 2021 Science paper is one of the most-cited human NMN trials. The design enrolled 25 postmenopausal women with prediabetes, randomized to 250 mg NMN or placebo daily for 10 weeks.

The primary endpoint was muscle insulin sensitivity by hyperinsulinemic-euglycemic clamp, which is a gold-standard method. The NMN group showed improvement in muscle insulin sensitivity relative to placebo. The effect size was statistically significant but modest in clinical terms.

Limitations to flag: the trial was small (25 patients total), short (10 weeks), single-center, and used a biomarker endpoint rather than clinical outcome. The population was specific (postmenopausal, prediabetic). Extrapolation to other populations or to harder outcomes isn’t supported by this trial alone.

The trial showed proof of concept that NMN can affect a metabolic readout in humans. It didn’t show that NMN should be used clinically for diabetes prevention or treatment.

What Did the Martens Et Al. NR Trial Show?

Martens and colleagues published a 2018 Nature Communications paper on NR in 24 healthy middle-aged and older adults. The crossover design tested 1000 mg NR daily for 6 weeks versus placebo.

Findings: NR raised whole-blood NAD+ by about 60%. Blood pressure dropped modestly in the NR period (systolic about 8 mmHg, diastolic about 4 mmHg). Aortic stiffness improved slightly. No significant effect on insulin sensitivity, exercise capacity, or several other secondary endpoints.

The blood pressure signal is interesting and has been partially replicated in other NR trials. It’s not large enough to make NR a serious antihypertensive treatment, but it suggests some cardiovascular effect.

Again, sample size was small (24 patients), follow-up was short (12 weeks total including washout), and the primary endpoint was an arterial stiffness biomarker rather than a clinical outcome.

What Other Notable NR and NMN Trials Exist?

A few worth knowing:

Conze et al. 2019 Scientific Reports: 140-patient NR trial in healthy adults at 100, 300, 1000 mg over 8 weeks. Confirmed dose-dependent rises in blood NAD+, well-tolerated, no major clinical effects in this short healthy-volunteer study.

Dollerup et al. 2018 American Journal of Clinical Nutrition: NR in obese, insulin-resistant men. Twelve weeks of 2000 mg daily. Raised NAD+ as expected. No significant effect on insulin sensitivity. This negative result is important and is sometimes underplayed in NMN/NR marketing.

Brakedal et al. 2022 Cell Metabolism: NR in Parkinson disease patients. Mild improvement in some biomarkers and clinical subscales. Encouraging but small (30 patients) and short (30 days).

Igarashi et al. 2022 npj Aging: NMN trial in older adults at 250 mg for 12 weeks. Some functional improvements in gait speed and grip strength. Small trial, modest effect sizes.

Trammell et al. 2017 Nature Communications: NR pharmacokinetics paper. Established the basic absorption and metabolism profile of NR in humans.

The pattern across trials: biomarkers move predictably, clinical outcomes are inconsistent, effect sizes are small relative to placebo.

What About IV NAD+ Trials?

The published RCT evidence for IV NAD+ is sparse. A few small observational studies and case series have looked at IV NAD+ in addiction recovery, fatigue, and aging populations. None have the design quality of the oral precursor trials.

A 2019 PK study by Grant et al. measured plasma NAD+ during 6-hour IV infusions in healthy volunteers. The data showed that most circulating NAD+ was metabolized to nicotinamide and other intermediates before significant cellular uptake. The cellular benefit, if any, comes from those downstream metabolites.

The marketing claims around IV NAD+ (energy, mood, anti-aging, addiction recovery) substantially exceed the published evidence. The infusions are expensive ($300 to $1500 per session) and physically uncomfortable. Whether they offer anything more than oral precursors at much lower cost is unproven.

What About NAD+ for Specific Conditions?

Parkinson disease: Brakedal et al. 2022 and a few other small trials suggest possible benefit. The N4PD trial is a larger trial looking at this question.

Alzheimer disease: Animal models suggest NAD+ supports neuronal function. Human trials are early.

Chronic fatigue and long COVID: High patient demand, limited rigorous data. Anecdotal reports and small open-label studies. RCTs in progress.

Heart failure: Small trials suggest possible cardiac mitochondrial benefits. Outcomes data is preliminary.

Sarcopenia and frailty: Small trials showing modest functional improvements. Larger trials needed.

Obesity: No clinical weight loss benefit shown. The Dollerup et al. trial in obese men was negative for insulin sensitivity.

Type 2 diabetes: Yoshino et al. showed muscle insulin sensitivity improvement in prediabetes. No major clinical diabetes outcomes data.

Cancer: Theoretical concern about supporting tumor cell DNA repair. No clinical trial signal of harm or benefit. Discuss with oncologist.

How Does This Compare to GLP-1 Trial Quality?

The contrast is striking and worth understanding.

The STEP program tested semaglutide in obesity across multiple trials with thousands of patients each. STEP 1 enrolled 1961 patients. SURMOUNT-1 enrolled 2539 patients. SELECT enrolled 17,604 patients for cardiovascular outcomes. FLOW enrolled 3533 patients for kidney outcomes. Trial durations were 68 weeks or longer, with primary endpoints that mattered to patients (weight, cardiovascular events, kidney disease progression).

The NAD+ trial program has no equivalent. The largest NAD+ trials are smaller than the smallest GLP-1 trial. The endpoints are biomarkers rather than outcomes. The durations are shorter.

This doesn’t mean NAD+ supplementation is useless. It means we don’t know what it does clinically with the kind of certainty Western medicine usually requires before recommending interventions. The marketing should match that uncertainty.

Key Takeaway: The most cited positive clinical trial is Yoshino et al. 2021 Science, which showed muscle insulin sensitivity improvement with NMN 250 mg in postmenopausal prediabetic women

What’s the Safety Record Across Trials?

Safety has been one of the more reassuring findings. Across published NR and NMN trials, adverse events have been mild and infrequent. Common reported events include occasional GI upset, mild headache, and very rarely sleep disturbance.

Liver enzymes have been monitored in many trials without clinically meaningful changes. No serious adverse events clearly attributable to NR or NMN have been reported in the major trials.

Long-term safety beyond 12 months is not well-characterized. Trial follow-up has been short.

Niacin (nicotinic acid) at gram doses has a different and worse safety profile, with hepatotoxicity and flushing risk. NR and NMN don’t share these issues.

What Does the Field Say About Lifespan Effects?

Honestly: nothing meaningful in humans. No trial has measured lifespan. The mouse data shows mixed results, with some studies showing median lifespan extension and others showing no effect or even harm in certain strains.

The David Sinclair sirtuin/NAD+ longevity hypothesis is mechanistically interesting but has not been validated by human outcomes data. The marketing tying NR or NMN to longevity is running on hope and mechanism, not on evidence of clinical benefit at the lifespan scale.

For context, the only human interventions with even partial evidence of mortality reduction are well-established things like statins for cardiovascular disease, metformin in diabetes (with some debated lifespan signal in observational data), and now GLP-1 medications with cardiovascular and renal outcome benefits.

What Ongoing Trials Might Change the Picture?

Several phase 2 trials are running in Parkinson disease, heart failure, sarcopenia, and various aging-related conditions. The N4PD trial in Parkinson disease is one of the larger ongoing studies. A few cardiovascular and metabolic disease trials are also recruiting.

Most of these are still relatively small (under 500 patients) and use biomarker or short-term clinical endpoints. A truly definitive trial powered for hard outcomes hasn’t been launched and may not happen without a major sponsor.

What About Head-to-head NR vs NMN?

Limited direct comparison data. Trials have generally tested one or the other, not both. The biomarker effects appear similar at comparable doses. The mechanistic debate about which is “better” hasn’t translated into clear clinical differences.

For practical purposes, pick based on cost, brand quality (third-party testing), and availability rather than on theoretical mechanistic preferences.

How Do I Read NAD+ Research News Critically?

A few principles:

First, distinguish biomarker findings from clinical outcomes. “NAD+ levels went up” is not the same as “people got healthier.”

Second, watch sample size. Trials under 50 patients can show effects that don’t replicate in larger trials.

Third, watch for industry funding. Most NR trials are funded by ChromaDex (the maker of Niagen). This doesn’t invalidate them but is relevant context. NMN trials have varied sponsorship.

Fourth, look for replication. Single positive trials often don’t hold up. Effects that show up across multiple independent groups are more credible.

Fifth, compare against placebo response. Subjective endpoints (energy, sleep, well-being) have large placebo effects in supplement trials. Effects in the same range as placebo aren’t convincing.

What’s the Bottom Line for a TrimRx Patient?

If you’re on a compounded semaglutide or tirzepatide protocol, the GLP-1 is doing the metabolic heavy lifting. The trial evidence for weight loss, glycemic improvement, cardiovascular event reduction, and kidney protection is strong and the effect sizes are large.

Adding NAD+ on top is not contraindicated and may have small marginal benefit on cellular energy biomarkers. It won’t substantially change the weight loss or metabolic outcomes of the GLP-1 protocol.

If you have budget after the GLP-1, protein, exercise equipment, and sleep optimization are covered, NAD+ supplementation at standard doses is a reasonable low-confidence addition. The evidence is preliminary but the safety profile is acceptable.

A free assessment quiz with TrimRx focuses on the GLP-1 protocol and what’s evidence-backed for weight management. Personalized treatment plans don’t include NAD+ as standard because the data doesn’t support it as core therapy.

Bottom line: For context, the GLP-1 evidence base includes STEP 1 (Wilding et al. 2021 NEJM, 14.9% weight loss in 1961 patients), SELECT (Lincoff et al. 2023 NEJM, 20% MACE reduction in 17,604 patients), and FLOW (Perkovic et al. 2024 NEJM, 24% kidney/CV event reduction)

FAQ

What’s the Single Strongest NAD+ Trial?

Yoshino et al. 2021 Science is one of the better-designed trials, with a gold-standard endpoint (clamp insulin sensitivity) and a clear hypothesis. It’s small and short, but well-conducted.

What Does the Meta-analysis or Systematic Review Evidence Look Like?

A few systematic reviews have summarized the NR and NMN human trial evidence. The general conclusions match what individual trials show: reliable NAD+ raising, modest and inconsistent clinical effects, good short-term safety. A 2023 systematic review of NMN trials in npj Aging found 10 published RCTs with mostly biomarker endpoints and called for larger trials with clinical outcomes. No meta-analysis has shown convincing pooled benefit for hard outcomes because the trials lack hard endpoints.

What About NAD+ for Skin and Appearance Specifically?

Several small trials have looked at topical or oral NR/NMN for skin aging biomarkers. Results are preliminary. Some show modest improvements in skin elasticity or hydration measurements. Whether this matters cosmetically in any meaningful way over months of use is unclear. The cosmetic peptide field is full of weak evidence and aggressive marketing across the board, not just for NAD+.

Has Any NAD+ Trial Been Negative?

Yes. Dollerup et al. in obese insulin-resistant men was negative for insulin sensitivity, despite raising NAD+. Several other secondary endpoints in various trials have been negative or null.

Are There Long-term Safety Trials?

Not well. The longest published trials are 12 to 24 weeks. Long-term observational data exists from users but isn’t trial-quality.

Do Industry-funded Trials Show Better Results Than Independent Ones?

The literature isn’t large enough to do a rigorous comparison, but funding source is always worth knowing. ChromaDex sponsors many NR trials. Look for replication by independent groups.

Is the Brain Pharmacology Established for NAD+?

Brain delivery of oral NR and NMN is modest in human studies. The brain pharmacology is one of the less-developed areas.

Should I Wait for Better Evidence Before Trying NAD+?

That’s a reasonable choice. The current evidence is suggestive but not compelling. If you want to try it at low cost and standard doses, the safety profile supports a trial.

What Would a Truly Definitive NAD+ Trial Look Like?

Multi-center, several thousand patients, hard clinical endpoint (cardiovascular events or mortality), 3 to 5 year follow-up, independent funding, pre-registered analysis plan. None has been done.

How Does the NAD+ Literature Compare to Other Peptide Claims Like NR for Longevity?

NR has better evidence than most longevity peptide claims because it’s been studied in actual humans with proper biomarker endpoints. But “better than mostly-rodent peptides” is not the same as “good enough to recommend.” Both standards matter.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.